当前位置： 当前位置：首页 > Fashion > WuXi Biologics Unlocking Potential with 18th GMP Release, Advancing Drug Substance to Product Capabilities 正文

**WuXi Biologics achieves milestone with 18th GMP release, solidifying global leader status in CRDMO**SHANGHAI, May 27, 2026 (PRNewswire) – WuXi Biologics, a pioneer and global leader in Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the successful achievement of its Drug Product Facility 15 (DP15) at its Fengxian site reaching all 18 Good Manufacturing Practices (GMP) requirements. This milestone underscores WuXi's unwavering commitment to advancing quality standards across all aspects of drug substance and product development, enabling seamless transition from preclinical research to final regulatory-compliant manufacturing.This latest achievement for WuXi Biologics is a testament to its dedication to excellence in every stage of the drug development process. The company has consistently demonstrated the ability to meet and exceed global regulatory requirements, which is crucial for maintaining trust and ensuring patient safety. By achieving all 18 GMPs, DP15 now fully aligns with international standards, solidifying WuXi's reputation as a trusted partner in the biopharmaceutical industry.The transition to meeting all 18 GMPs involved overcoming significant challenges, including the rigorous testing of new manufacturing processes and equipment. WuXi Biologics' team of expertise in process development, quality control, and regulatory compliance played a pivotal role in this accomplishment. The company's ability to consistently deliver high-quality manufacturing capabilities is a key factor in its sustained leadership in CRDMO.In today’s competitive global market, meeting all 18 GMPs is a major achievement for any biotechnology or pharmaceutical organization. WuXi Biologics has demonstrated time and again that it can expand its manufacturing capabilities while maintaining the highest standards of quality and efficiency. This milestone not only highlights the company's technical prowess but also reinforces its position as a leader in advancing drug substance to product.WuXi Biologics' commitment to continuous improvement is reflected in its ability to integrate innovative process development with rigorous regulatory compliance, ensuring that all manufacturing activities meet the highest standards of quality and consistency. With this milestone achieved, the company continues to drive innovation across the entire spectrum of drug development processes.As CRDMOs play an increasingly critical role in accelerating drug development by reducing costs and enhancing efficiency, WuXi Biologics remains at the forefront of this evolution. Its expertise in scaling up manufacturing capabilities while maintaining product quality positions it as a vital partner for biopharmaceutical companies worldwide.Looking ahead, WuXi Biologics is poised to expand its capabilities further, continuing to meet evolving regulatory requirements and supporting the entire drug development process from early-stage discovery through to final product commercialization. With its unwavering commitment to excellence and innovation, WuXi Biologics will continue to be a trusted partner for clients seeking reliable and efficient manufacturing solutions.In conclusion, the achievement of all 18 GMPs by WuXi Biologics DP15 is a significant milestone in its ongoing journey of delivering high-quality manufacturing capabilities. This accomplishment underscores the company's dedication to excellence and its role as a leader in advancing drug substance to product. As the biopharmaceutical industry continues to evolve, WuXi Biologics remains committed to driving innovation, enhancing efficiency, and ensuring patient safety through robust manufacturing practices.**#WuXiBiologics #GMP18 #CRDMO #DrugDevelopment #PharmaceuticalManufacturing